Most Popular in the Last...

Home

Brett Wilson

See the following -

TransCelerate BioPharma Inc. Publishes Risk-Based Monitoring Recommendations For Central Monitoring And Technology Considerations

Press Release | TransCelerate BioPharma Inc. | September 17, 2014

TransCelerate BioPharma Inc. ("TransCelerate") announced today the publication of its two most recent manuscripts on risk-based site monitoring ("Risk-Based Monitoring" or "RBM"), developed jointly by its 19 member companies. Both manuscripts have been accepted and published through the Drug Information Association's Therapeutic Innovation & Regulatory Science journal...

Read More »

TransCelerate Shares Its Take On Risk-Based Monitoring Models And Tech

Nick Paul Taylor | Fierce BioTech IT | September 20, 2014

With clinical trial sponsors spending a sizable chunk of their huge Phase III trial budgets on source data verification (SDV) in return for questionable benefits, risk-based monitoring is an obvious target for TransCelerate BioPharma's R&D efficiency agenda. The Big Pharma consortium has further clarified its thinking on the topic in two research papers...

Read More »